NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis $3.65 -0.09 (-2.41%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$3.66 +0.00 (+0.14%) As of 03/28/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Voyager Therapeutics Stock (NASDAQ:VYGR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Voyager Therapeutics alerts:Sign Up Key Stats Today's Range$3.62▼$3.7750-Day Range$3.64▼$5.6652-Week Range$3.56▼$10.66Volume277,697 shsAverage Volume466,170 shsMarket Capitalization$201.51 millionP/E Ratio5.14Dividend YieldN/APrice Target$13.97Consensus RatingBuy Company OverviewVoyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More… Remove Ads Voyager Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreVYGR MarketRank™: Voyager Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 62nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingVoyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVoyager Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Voyager Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Voyager Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 5.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 5.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.55.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.39% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 4.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.97 Percentage of Shares Shorted5.39% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 4.07%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment1.51 News SentimentVoyager Therapeutics has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Voyager Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,823.00 in company stock.Percentage Held by InsidersOnly 4.53% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Stock News HeadlinesVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.97 Consensus PT from AnalystsMarch 30 at 1:31 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 17, 2025 | prnewswire.comWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Oracle"—known for spotting Apple, Amazon, and Google early—has identified a firm with patented tech that could become essential to every major AI player. He shares the name and ticker in this free video—but warns the opportunity could vanish once it hits the mainstream.March 30, 2025 | InvestorPlace (Ad)Voyager Therapeutics price target lowered to $12 from $14 at CanaccordMarch 13, 2025 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 AnalystsMarch 12, 2025 | benzinga.comVoyager Therapeutics price target lowered to $10 from $12 at Wells FargoMarch 12, 2025 | markets.businessinsider.comWells Fargo Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)March 12, 2025 | markets.businessinsider.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comSee More Headlines VYGR Stock Analysis - Frequently Asked Questions How have VYGR shares performed this year? Voyager Therapeutics' stock was trading at $5.67 at the start of the year. Since then, VYGR stock has decreased by 35.6% and is now trading at $3.65. View the best growth stocks for 2025 here. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings results on Tuesday, March, 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.24. The firm earned $4.39 million during the quarter, compared to analysts' expectations of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a trailing twelve-month return on equity of 8.33%. Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' top institutional shareholders include Vanguard Group Inc. (5.89%), Farallon Capital Management LLC (4.71%), Dimensional Fund Advisors LP (2.53%) and Vestal Point Capital LP (2.25%). Insiders that own company stock include Neurocrine Biosciences Inc, Rock Ventures Iii LP Third, Ecor1 Capital, Llc, Robin Swartz, Robert W Hesslein, Todd Alfred Carter, Sandell Jacquelyn Fahey and Glenn Pierce. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings3/11/2025Today3/29/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VYGR CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$13.97 High Stock Price Target$30.00 Low Stock Price Target$5.73 Potential Upside/Downside+282.6%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E Ratio5.14 Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins15.80% Pretax Margin16.35% Return on Equity8.33% Return on Assets6.15% Debt Debt-to-Equity RatioN/A Current Ratio8.45 Quick Ratio8.45 Sales & Book Value Annual Sales$80.00 million Price / Sales2.52 Cash Flow$2.59 per share Price / Cash Flow1.41 Book Value$5.37 per share Price / Book0.68Miscellaneous Outstanding Shares55,207,000Free Float52,151,000Market Cap$201.51 million OptionableOptionable Beta0.99 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:VYGR) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.